Evidence map›Paper›PMID 31541541›Full record

ArticleEthics & human research2019

Reported Participation Benefits in International HIV Prevention Research with People Who Inject Drugs.

Jeremy Sugarman, Ilana Trumble, Erica Hamilton, Riza Sarasvita, Kostyantyn Dumchev, Ha Viet, Irving Hoffman, William Miller, Brett Hanscom

Open access · greenAbstract read
In one paragraph

Article in Ethics & human research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Jeremy SugarmanHarvey M. Meyerhoff professor of bioethics and medicine at the Berman Institute of Bioethics and the Department of Medicine at Johns Hopkins University.
Ilana TrumbleResearch assistant and PhD student in the Department of Biostatistics and Informatics at the Colorado School of Public Health.
Erica HamiltonClinical research manager with the HPTN Leadership and Operations Center at FHI 360.
Riza SarasvitaDirector of Strengthening Government-based Rehabilitation Centre of the Indonesia National Narcotics Board.
Kostyantyn DumchevScientific director at the Ukrainian Institute on Public Health Policy.
Ha VietInvestigator of record of HPTN 074 in Pho Yen CRS Vietnam and a research assistant professor in the Department of Health Behavior at the University of North Carolina Gillings School of Public Health.
Irving HoffmanProfessor of medicine and the director of international operations for the University of North Carolina Institute of Global Health and Infectious Diseases.
William MillerProfessor in and the chair of the Division of Epidemiology in the College of Public Health at The Ohio State University.
Brett HanscomBiostatistician with the Statistical Center for HIV Research and Prevention in Seattle.
Colorado School of Public Health · USFamily Health International 360 · USGovernment of the United States of America · USJohns Hopkins University · USThe Ohio State University · USUkrainian Institute of Public Health Policy · UA

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
NIAID NIH HHS P30 AI050410NIAID NIH HHS UM1 AI068619
6 · The paper itself

Abstract

Given ethical concerns about research involving people who inject drugs and those affected by HIV, identifying potential participation benefits is important. We evaluated participant-reported benefits in a trial conducted in Indonesia, Ukraine, and Vietnam that assessed an intervention combining psychosocial counseling and referral for antiretroviral therapy and substance use treatment for HIV-infected people who use drugs. Reported benefits were aggregated into three groups: clinical (antiretroviral therapy, reduced cravings, reduced drug use, lab testing, medical referral, mental health, physical health), social (employment, financial, relationships, reduced stigma), and general (gained knowledge, life improvement). Overall, 438 index participants (90.5%) and 642 injection partners (83.1%) reported at least one benefit. Significantly more index participants who received the study intervention reported at least one benefit versus those who received the standard of care. Clinical trial participation can provide broad direct and indirect benefits for stigmatized populations, which has implications for assessing the ethical appropriateness of studies with such populations.

Indexed as

CounselingHarm ReductionAnti-Retroviral AgentsFemaleHIV InfectionsHumansIndonesiaInternationalityMaleSocial StigmaSubstance Abuse, IntravenousUkraineVietnamAnti-Retroviral AgentsHIV clinical trialsHuman subjects researchpeople who inject drugsresearch benefitsresearch risks

Identifiers

PMID31541541
PMCPMC8792865
OpenAlexW2973826316

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.